These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 34598728)

  • 21. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
    Lorenzoni V; Pirri S; Turchetti G
    Clin Drug Investig; 2021 Mar; 41(3):255-267. PubMed ID: 33587284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
    Simonyi G; Ferenci T; Finta E; Gasparics R; Medvegy M
    Orv Hetil; 2019 Mar; 160(13):509-515. PubMed ID: 30907102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing.
    Moudallel S; Steurbaut S; Cornu P; Dupont A
    Front Pharmacol; 2018; 9():1220. PubMed ID: 30425641
    [No Abstract]   [Full Text] [Related]  

  • 24. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication errors in relation to direct-acting oral anticoagulants: a qualitative study of pharmacists' views and experiences.
    Al Rowily A; Aloudah N; Jalal Z; Abutaleb M; Baraka M; Paudyal V
    Int J Clin Pharm; 2023 Jun; 45(3):681-688. PubMed ID: 36976394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients.
    Umei M; Kishi M; Sato T; Shindo A; Toyoda M; Yokoyama M; Matsushita M; Ohnishi S; Yamasaki M
    J Arrhythm; 2017 Oct; 33(5):475-482. PubMed ID: 29021853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
    Monreal-Bosch M; Soulard S; Crespo C; Brand S; Kansal A
    Rev Neurol; 2017 Mar; 64(6):247-256. PubMed ID: 28272725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants.
    Cohen AT; Hill NR; Luo X; Masseria C; Abariga SA; Ashaye AO
    Int J Cardiol; 2018 Oct; 269():174-181. PubMed ID: 30037626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.
    Mueller T; Alvarez-Madrazo S; Robertson C; Wu O; Bennie M
    Br J Clin Pharmacol; 2019 Feb; 85(2):422-431. PubMed ID: 30423191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience.
    Elewa H; El-Makaty H; Ali Z
    J Cardiovasc Pharmacol Ther; 2018 Mar; 23(2):155-161. PubMed ID: 28978236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions.
    Monaco L; Biagi C; Conti V; Melis M; Donati M; Venegoni M; Vaccheri A; Motola D
    Br J Clin Pharmacol; 2017 Jul; 83(7):1532-1543. PubMed ID: 28071818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dosing Accuracy of Direct Oral Anticoagulants in an Academic Medical Center.
    Schwartz J; Merrill S; de Leon N; Thompson A; Fang M
    J Hosp Med; 2017 Jul; 12(7):544-550. PubMed ID: 28699943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program.
    Perlman A; Horwitz E; Hirsh-Raccah B; Aldouby-Bier G; Fisher Negev T; Hochberg-Klein S; Kalish Y; Muszkat M
    Isr J Health Policy Res; 2019 Feb; 8(1):19. PubMed ID: 30709417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
    Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M
    Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data.
    Hirschl M; Kundi M
    Vasa; 2019 Mar; 48(2):134-147. PubMed ID: 30376416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.